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Abstract
Activated platelets are key components in many arte-
rial disorders. P-selectin is an activation-dependent
platelet receptor, which is also identified in endothe-
lial cells. Together with E- and L-selectin it constitutes
the selectin family. These transmembrane proteins
have continued to attract great interest as they sup-
port rapid and reversible cell adhesion in flow sys-
tems and thus play an essential role in multicellular
interactions during thrombosis and inflammation.
Similarly to other lectins, selectins bind to different
glycoconjugates with varying affinities. Protein
ligands, equipped with the appropriate carbohydrate
and sulfate moieties for P-selectin binding, have been
identified in normal peripheral blood leukocytes and
several non-hematopoietic organs, as well as on can-
cer cells. For diagnostic purposes, P-selectin can read-
ily be detected on the platelet surface by flow
cytometry and by ELISA as a soluble ligand in the
plasma. Along with other markers, these data can be
used in the assessment of platelet activation status.
Such results bear clinical significance since P-selectin
has been implicated in the pathogenesis of wide-
spread disorders including coronary artery disease,
stroke, diabetes and malignancy.
Keywords: microparticle; platelet; P-selectin; P-selec-
tin glycoprotein ligand-1 (PSGL-1); vascular disorders.
Brief historical background
The year 2004 marks the 20th anniversary of the dis-
covery of P-selectin (Granule Membrane Protein-140,
GMP-140; CD62). In 1984, a monoclonal antibody
(S12) was described that bound only to activated
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platelets and the expression of this protein paralleled
with serotonin release (1). Simultaneously, another
group also identified a platelet receptor with the anti-
body KC4 in thrombin-activated platelets that they
called platelet activation-dependent external granule
membrane (PADGEM) protein (2). Later it became evi-
dent that the two groups had identified the same pro-
tein. It is a 140 kDa transmembrane glycoprotein that
was subsequently designated as GMP-140 (3) and
most of its mass is located on the extra-cytoplasmic
face of the membrane (4). In the same year, it was
demonstrated that GMP-140 was located in the Wei-
bel-Palade bodies of vascular endothelial cells as well
(5, 6). P-selectin belongs to the selectin family (P-, L-
and E-selectins) and constitutes a gene cluster on
mouse and human chromosome 1 (7). The biological
function of the P-selectin molecule was not evident
until it was shown that it mediates the interaction of
activated platelets with myeloid cells (8, 9). A similar
function was also observed for the endothelial P-
selectin as well (10). One major question remained
open for quite some time. Though both platelet and
endothelial P-selectin were found to bind to a leuko-
cyte surface receptor, the ligand was not yet identi-
fied. Despite strong evidence for a lectin-like
interaction (11), Larsen et al. first thought that the
ligand was the lineage-specific CD15 (12). However,
in 1992 Moore et al. were the first to identify a specific
glycoprotein ligand for P-selectin on myeloid cells
(13). This dimeric mucin was later cloned and desig-
nated as P-selectin glycoprotein ligand-1 (PSGL-1)
(14). Subsequent studies have shown that it also func-
tions as a major ligand for L-selectin and to a lesser
extent for E-selectin. The past decade has witnessed
a plethora of publications on P-selectin, verifying its
role as a pathogenetic factor in different multicellular
adhesive interactions. Currently, P-selectin is consid-
ered as an important disease marker as it participates
in many pathological conditions that range from ath-
erosclerosis and inflammation to various psychiatric
disorders.
Structure and function of selectins
Lectins are carbohydrate-binding proteins that have a
fairly logical nomenclature. This family of proteins is
divided into several sub-families depending on their
requirements for binding: C-type lectins (calcium),
S-type lectins (free thiol groups), P-type lectins (man-
nose-phosphate) I-type lectins (immunoglobulin
superfamily). The selectins as a member of the C-type
lectins mediate adhesion of platelets and leukocytes
to the vascular surface. All selectins consist of a lectin
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Figure 1 Domain structure of selectins. The mature selec-
tins share the same structural elements: a short intracyto-
plasmic domain, a transmembrane domain, a varying
number of consensus repeats, an EGF domain and a lectin
domain that interacts with glycosulfopeptides.
Table 1 Ligands of various selectins.
Cell type Protein ligands Major inducers
P-selectin Activated endothelium PSGL-1 Thrombin
(GMP-140, PADGEM, CD62P) and platelets CD24 Histamine
Complement derivates
Peroxides
E-selectin Activated endothelium PSGL-1 IL-1
(ELAM-1, CD62E) ESL-1 TNF-a
L-Selectin LPS
L-selectin Memory lymphocytes, PSGL-1 IL-1
(MEL-14, CD62L) neutrophils, monocytes, GlyCAM-1 TNF
macrophages, eosinophils MAdCAM-1 IF-g
CD34 LPS
Podocalyxin
Abbreviations: IL-1, interleukin-1; TNF-a, tumor necrosis factor-a LPS, lipopolysaccharide; IF-g, interferon-g.
domain followed by an epidermal growth factor like
module, a varying number of short consensus
repeats, a transmembrane domain and a short cyto-
plasmic tail (Figure 1).
L-selectin is constitutively expressed on the leuko-
cyte surface. However, stimulation of bone marrow
leukocytes could result in either up- or down-regula-
tion of cell surface expressed L-selectin depending on
the agonist (15). E-selectin is expressed only on acti-
vated endothelial cells and P-selectin appears on the
surface of stimulated platelets and endothelial cells.
A recent report also suggests that peritoneal macro-
phages express P-selectin (16). These selectins can
interact with their respective glycoprotein (mucin)
ligands on lymph node vessels, endothelium and leu-
kocytes, thus selectins may catalyze multiple cellular
interactions. The selectins and their counter receptors
are described in Table 1.
All three selectins can bind to PSGL-1, however,
appropriate carbohydrate decoration and sulfation of
PSGL-1 are necessary for it to reach its optimal capac-
ity to interact with P- and L-selectins (17, 18). Data to
date suggest that sulfation of PSGL-1 is dispensable
for binding to E-selectin (19, 20). It appears that the
requirement on carbohydrate decoration is also less
stringent for the mucin ligands to bind E-selectin. The
interaction of human lectins with their counter recep-
tors is rapid and reversible, thus making this bond
ideal for mediating rolling adhesion under hydrody-
namic stress, like in flowing blood. L-selectin binds to
its ligands on high endothelial venules of lymph
nodes and on activated endothelial cells at sites of
inflammation. E- and P-selectins on activated endo-
thelial cells bind to their respective ligands on leuko-
cytes. P- and L-selectins are primarily responsible for
the tethering of flowing leukocytes to the endotheli-
um, but they also support rolling and subsequent leu-
kocyte activation. E-selectin is particularly important
for slowing rolling velocities of leukocytes after they
have been tethered through P- or L-selectin. The
resultant long transit times are essential for efficient
leukocyte adhesion in response to local chemotactic
stimuli (21). It mediates the adhesion of blood neutro-
phils involved in the regulation of inflammatory and
immunological events at the interface of the vessel
wall and blood (22).
The expression of P- and E-selectins on the endo-
thelial cells is regulated by different mechanisms.
Newly synthesized P-selectin is first transported to
Weibel-Palade bodies. Upon stimulation with inflam-
matory mediators such as histamine and thrombin,
these storage granules fuse with the plasma
membrane, resulting in rapid redistribution of P-selec-
tin on the cell surface. The appearance of P-selectin
on the endothelial cell surface reaches its peak
3–4 minutes following stimulation and then declines
to basal level within 30 minutes. Since P-selectin is
co-localized with von Willebrand factor (vWF) in the
Weibel-Palade bodies, the expression of P-selectin is
concomitant with the release of vWF. Complement
activation leading to membrane deposition of the
C5b-9 proteins causes the release of very high molec-
ular weight vWF multimers, which is accompanied by
expression of P-selectin on the endothelial surface
(23). More recently it was shown that P-selectin
anchors the newly released large vWF multimers to
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the endothelial surface (24). P-selectin on both the
endothelial cell and platelet surface are present in the
form of monomers as well as non-covalent dimers
(25). Unlike P-selectin, E-selectin is de novo synthe-
sized after appropriate endothelial stimulation, thus it
takes at least 4 hours until E-selectin reaches its opti-
mal expression on the endothelial cell surface. The
dynamics of their appearance on, and the disappear-
ance from, the cell surface is crucial to mediate cell
adhesion. The mechanisms that regulate their cell-
surface expression are important to determine their
adhesive capacity. It has recently been described that
platelet P-selectin expression requires protein kinase
C, but not protein tyrosine kinase or phosphoinositide
3-kinase (26). Once expressed on the cell surface,
platelet P-selectin remains there until it is shed into
the plasma (27), whereas endothelial P-selectin is rap-
idly internalized in clathrin-coated pits (28). Clustering
of P-selectin in clathrin-coated pits enhances its
capacity to mediate leukocyte adhesion in flow con-
ditions (29).
Interactions and signaling via PSGL-1
The best characterized ligand for P-selectin binding is
PSGL-1. The binding of P-selectin to PSGL-1 is
Ca2qdependent and is abolished by treatment of the
ligand with sialidase. The O-linked glycans are
required for P-selectin recognition, whereas the N-
linked glycans are not. The ability of PSGL-1 to medi-
ate neutrophil rolling on P-selectin has been
demonstrated in both ex vivo and in vivo experiments
(30, 31). The potency of this molecular interaction to
support rolling has been verified as microspheres
coated with PSGL-1 roll on P-selectin. However, cel-
lular properties are indispensable to stabilize rolling
over a wide range of shear stresses (32).
For the appropriate biochemical responses it is
important that the PSGL-1 communicates with intra-
cellular proteins. Indeed the association of the PSGL-
1 cytoplasmic domain with the actin cytoskeleton is
crucial for rolling on P-selectin. Higher doses of an
actin cytoskeleton inhibitor dramatically reduce roll-
ing on P-selectin in a dose-dependent fashion. This
observation suggests that disruption of the pre-exist-
ing actin cytoskeletal network impairs PSGL-1-medi-
ated rolling. PSGL-1 requires interactions between its
cytoplasmic domain and the actin cytoskeleton, but
not de novo polymerized actin, for leukocyte rolling.
PSGL-1 is indirectly linked to the cytoskeletal network
via the ERM protein moesin (33). The intracellular sig-
nals generated by P-selectin PSGL-1 interaction are
largely unknown. The cross-linking of PSGL-1 with an
anti-PSGL-1 monoclonal antibody (PL1) or adhesion
to P-selectin results in tyrosine phosphorylation. This
signaling event does not require co-ligation of Fcg
receptors. PL1 increases tyrosine phosphorylation in
neutrophils pretreated with cytochalasin B, suggest-
ing that an intact cytoskeleton is not required for this
response. This phosphorylation event is important as
PSGL-1 stimulates secretion of IL-8 through a tyrosine
phosphorylation dependent pathway (34).
The engagement of neutrophil PSGL-1 by P-selectin
is followed by neutrophil activation including b2 inte-
grin activation, which subsequently results in stable
cell-cell interaction. This 2-step model of platelet-leu-
kocyte interaction highlights that there is cross-talk
between P-selectin and the b2 integrin CD11b/18 (35).
The subsequent events are the result of the net
changes on the leukocyte surface as activation of leu-
kocytes reduces surface PSGL-1 expression and adhe-
sion to P-selectin in vitro (36). Although various
inflammatory agents could induce similar densities of
P-selectin on the endothelial cell surface, their capac-
ity to mediate leukocyte adhesion in flow conditions
could be different. This was shown in a recent study,
which demonstrated that thrombin-induced activation
of RhoA reduces the cell-surface distribution of P-
selectin in clathrin-coated pits and thereby the adhe-
sive capacity of P-selectin (37).
The clinical laboratory approach to P-selectin
analysis
It is obvious that for clinical laboratory technicians,
the measurement of endothelial P-selectin is mostly
not accessible. However, there are still two possible
routes for routine analysis: they are platelet P-selectin
and soluble P-selectin (sPsel) measurements.
Platelet P-selectin
Flow cytometry is an advantageous technique for the
analysis of platelet receptors. Thus, it is no surprise
that the first flow cytometric study of platelet P-selec-
tin was published soon after its discovery (38). In an
early paper, Ault et al. described the optimal meas-
uring conditions and the optimization of pre-analytical
variables for platelet P-selectin analysis (39). Their
whole blood flow cytometric assay of platelet activa-
tion using a fixed specimen has been increasingly
used in recent years to assess platelet function in clin-
ical research settings. This approach offers several
advantages over other clinical tests of platelet func-
tion including relative simplicity, minimal manipula-
tion of samples, preventing artifactual in vitro platelet
activation, analysis in the physiological milieu of
whole blood, high sensitivity for the detection of
platelet subpopulations and the need for onlyminimal
blood volumes. A theoretical disadvantage of flow
cytometry relates to the possibility that activated
platelets may display a decreased survival in circula-
tion, resulting in modest or non-evident platelet acti-
vation by flow cytometric analysis (40, 41). However,
convincing experimental data support that activated
platelets continue to circulate. Thus, platelet activa-
tion is not necessarily the ultimate stage of platelet
life (42, 43).
The pre-analytical conditions are extremely impor-
tant in the analysis of platelet activation markers.
Whole blood observation is suitable for the detection
of platelet activation status (PAS), avoiding activation
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Table 2 Different sensitivity of direct platelet activation markers.
Thrombin, U/ml P-selectin, % P-selectin MFI GPIX MFI Microparticle, %
0 2 60 182 2
0.01 8 65 163 2
0.02 20 69 171 2
0.03 48 116 109 2
0.05 66 142 124 3
0.1 85 168 110 9
Citrated whole blood sample was stimulated with increasing thrombin concentrations. P-selectin expression, the mean fluo-
rescence intensity (MFI) of P-selectin staining, GPIX fluorescence and the percentage of events in the microparticle gate were
registered. P-selectin expression was sensitive to even miniscule amounts of thrombin.
during platelet isolation. In addition, rapid fixation of
blood after venipuncture is also important. P-selectin
values of platelet-rich plasma (PRP) often result in
higher control values compared to whole blood anal-
yses (44). We also found that the preparation of PRP
resulted in a random up-regulation of P-selectin. Most
authors in different clinical studies found 1–2% posi-
tivity for platelet P-selectin in control subjects by
whole blood analysis. Values above this rate mean an
enhanced PAS and may predict a hypercoagulable
state. More recently the presence of monocyte-plate-
let aggregates has been shown to be a superior indi-
rect marker of platelet activation in in vitro
experiments and in ex vivo samples (45, 46). How-
ever, compared to other platelet markers at low
thrombin concentrations, platelet P-selectin sensitive-
ly reflects the status of platelet activation (Table 2). At
higher thrombin doses platelets are fragmented,
which is easily detectable by scatter analysis (Figure
2). It seems that a method using minimal preparatory
steps is the most useful for platelet flow cytometric
analysis.
Aside from P-selectin, a panel of tests using other
antibodies (e.g., CD63, PAC-1), as well as indirect tests
like monocyte-platelet aggregates or monocyte tissue
factor expression, can be the most reliable approach
for the characterization of activated platelets.
Soluble P-selectin
In addition to being a platelet membrane receptor, P-
selectin can be identified as a circulating plasma pro-
tein. In normal plasma, sPsel concentration showed a
difference between genders, being higher in males
(47, 48). It seems that the primary contributors to the
formation of sPsel in the physiological state are plate-
lets and thus baseline concentrations are mostly
determined by platelet P-selectin shedding. The pos-
itive correlation between platelet count and the level
of sPsel also supports this conclusion. In patients with
bone-marrow aplasia, the sPsel concentration is
reduced but is not completely absent. The remaining
sPsel in bone marrow aplasia could be derived from
a few persisting megakaryocytes and/or platelets or
from endothelial cells. Therefore, a minimal release
of sPsel from endothelial cells under normal condi-
tions cannot be excluded (49). Verhaar et al. found
that progression of vascular, endothelial damage in
essential, renovascular and malignant hypertension is
associated with a rise in circulating levels of P-selec-
tins, which also confirms the link between sPsel and
endothelial cells as a source of this protein (50). The
shedding mechanism of P-selectin has not been
exactly elucidated. The cathepsin G- and neutrophil
elastase-mediated PSGL-1 proteolysis may constitute
a potential autocrine mechanism for down-regulation
of neutrophil adhesion to P-selectin but not for shed-
ding for P-selectin itself (51). Though no direct proofs
have been reported, metalloproteinases might be can-
didates causing P-selectin shedding, as has been
found for L-selectin (52). Receptors are also shed from
the surface of activated platelets by the generation of
microvesicles from the plasma membrane. These
microvesicles appear to contain all the major
membrane glycoproteins but are depleted in those
that have been removed from the platelet membrane
by proteolytic cleavage (53). When microparticles
(MPs) are isolated from normal human plasma, a
large part of the MPs express the platelet marker GPIX
and nearly half of the platelet-derived MPs are P-
selectin positive (Figure 3).
Though MPs express a significant amount of P-
selectin it has been shown that the majority of sPsel
in plasma is not associated with MPs (54). However,
sPsel is not simply a platelet activation marker. In for-
mer studies, there was a controversy on whether P-
selectin is itself an inducer (55) or rather a supporter
of leukocyte responses induced by other agonists
(56). Either way, there is a procoagulant state that
results from high levels of sPsel in blood (57). The
concentration of sPsel is determined by ELISA. In nor-
mal subjects, it is mostly found in the 100–200 ng/ml
range. The comparison of sPsel data from different
groups in the literature is not always easy. Most of
the sPsel values measured by reagents from R&D
System (Abingdon, UK) have values for control sub-
jects in the 20–100 ng/ml range (58–60), while sPsel
values of plasmas from healthy subjects as quantified
by the Takara Biomedicals ELISA kit (Takara Shuzo
Ltd., Shiga, Japan) are mostly in the range of 150–
250 ng/ml (61, 62). These differences may partly be
explained by the different antibodies used in the ELI-
SA kits. The Takara assay uses two monoclonal anti-
bodies while the R&D kit utilizes a monoclonal
capture antibody and a peroxidase-conjugated poly-
clonal antibody for detection. In addition to these
methodological variations, differences in blood sam-
pling and sample processing and ethnic background
may also account for the observed results.
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Figure 2 Scatterplots and P-selectin expression in unstimulated and thrombin-stimulated platelets. Platelets were labeled
with FITC-conjugated anti-GPIX and PE-conjugated CD62 antibody in unstimulated platelets (panels A, D) and in samples
stimulated by 0.05 U/ml thrombin (panels B, E) and by 0.5 U/ml thrombin (panels C, F) in the presence of RGDS peptide. In
scattergrams the R1 regions depict the platelet gate while R2 depicts the microparticle gate. In the fluorescence plots the P-
selectin-positive platelets are described in the upper right quadrant. P-selectin expression reaches maximal value already at
a low thrombin dose while a significant increase of the event count in the microvesicle gate is only evident at a high thrombin
dose.
P-selectin: a disease marker
Thrombosis and cardiac diseases
The initial steps of atherosclerosis are associated with
endothelial cell dysfunction, the development of their
prothrombotic activity and with increased adhesive-
ness for platelets and leukocytes. Different interac-
tions between platelets and endothelial cells through
P-selectin binding generate signals to recruit inflam-
matory cells to the site of vascular injury and promote
the extravasation of leukocytes to the inner layers of
the vessel wall. Platelets that accumulate at the site
of arterial injury can also more directly recruit mono-
cytes to the vessel wall through PSGL-1-P-selectin
interaction. Monocyte-platelet aggregates have been
identified in the peripheral blood of patients with cor-
onary artery disease and may serve as markers of dis-
ease activity (63, 64). In thrombotic consumptive
disorders sPsel levels were found to be elevated by
several authors (65, 66).
P-selectin as an adhesion molecule plays an impor-
tant role in atherosclerosis (67). In the P-selectin-defi-
cient mice a number of defects in leukocyte adhesion
are observed, notably: total absence of leukocyte roll-
ing and delayed recruitment of neutrophils, thus dem-
onstrating the important role of P-selectin in these
processes (68). Furthermore, P-selectin-deficient mice
on an atherogenic diet formed significantly smaller
fatty streaks in aorta than did P-selectin-positive mice
(69). Similarly to the studies in P-selectin knockout
animals, in vivo studies using P-selectin blocking anti-
bodies proved to be very conclusive. In animal stud-
ies, administration of monoclonal antibodies (PB1.3,
NBP1.6) against P-selectin resulted in infarct size
reduction. They significantly decreased adherence of
non-stimulated polymorphonuclear leukocytes
(PMNs) to thrombin and histamine-stimulated endo-
thelial cells, exerting significant endothelial preser-
vation and cardioprotection in myocardial ischemia
(70). Furthermore, P-selectin blocking accelerated
pharmacological thrombolysis in a primate model of
arterial thrombosis (71).
In another approach (72) it was found that in the
atherosclerosis prone apolipoprotein E (apoE)-defi-
cient mouse model, P-selectin facilitated atheroscle-
rotic lesion development. In states of extracorporeal
circulation, platelets were found to be activated (73–
75) and it is quite possible that the leukocyte activa-
tion we previously observed in such states (76, 77) is
associated with prior platelet activation. P-selectin
expression correlates well with early and advanced
lesion development, so it has become a candidate tar-
get for anti-atherogenic strategies and its ligands can
be considered as promising tools to target or antag-
onize P-selectin function within the chronically
inflamed arterial wall (78). Platelets adhere to dam-
aged endothelial cells and collagen while becoming
activated, causing inflammation by releasing the con-
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Figure 3 P-selectin expression is different in intact platelets and microparticles. In unstimulated whole blood, platelet P-
selectin is only 2% (panels A, C). The majority of the microparticles separated from the same sample are of platelet origin
(GPIX positive) and 54% of them express P-selectin (panels B, D).
tents of their granules in peripheral vessels. In
patients with peripheral arterial disease, platelets are
hyperactivated and circulate in an activated state (79,
80). A recent review summarizes the importance of
P-selectin in cardiovascular disease (81).
Venous thrombosis
In addition to the role of P-selectin in arterial throm-
bosis, it could also be responsible for enhanced plate-
let activation in deep venous thrombosis (DVT). sPsel
was found to be increased in patients with DVT and
may be a reflection of a generalized hypercoagulable
state of platelets when thrombus was present (82, 83).
This hypothesis has been confirmed by studies on
inhibiting P-selectin by a selectin antagonist, the
recombinant PSGL-1 immunoglobulin that decreased
inflammation and limited venous thrombosis (84, 85).
Elevated levels of P-selectin can amplify thrombosis
mediated by procoagulant MPs. E- and P-selectin
gene-interrupted mice (EPKO) had the smallest
thrombi compared to wild-type animals and mice
with high circulating levels of sPsel (CT). A significant
difference was noted between the CT and EPKO
groups for neutrophils, monocytes and total inflam-
matory cells (86). It was observed that mice lacking
PSGL-1 or P-selectin, or wild-type mice infused with
blocking P-selectin antibodies, developed thrombi
with minimal tissue factor and fibrin. They indicated
that one pathway for the inhibition of blood coagu-
lation in vivo involves the accumulation of tissue fac-
tor- and PSGL-1-containing MPs in the platelet
thrombus expressing P-selectin (87).
Stroke
The increased risk of stroke may be related to the
prothrombotic or hypercoagulable state with abnor-
malities of hemostasis including platelet activation.
The participation of activated platelets in the devel-
opment of focal ischemia was already suspected in
the 1960s. Marquardt et al. determined the rate of
healthy control subjects below 2% P-selectin positivity
and they found a 2- to 2.5-fold increase in CD62 pos-
itivity in patients at the first day after cerebral ische-
mia. The P-selectin level then decreased gradually
from the second day and reached the normal rate
90 days after stroke. No correlation was found
between inflammatory markers (fibrinogen, leukocyte
count, C-reactive protein) and the degree of platelet
activation (88). A relatively high level of platelet P-
selectin expression was observed in cardioembolic
stroke (CES) by Yamazaki et al. Two to four percent
of P-selectin expressed platelets were measured in
CES patients compared to the 1–1.5% observed in
healthy controls (89). In other studies, the increased
expression of P-selectin on platelets (7.6"0.9% vs.
4.8"0.7%) was associated with reduced NO levels
and was a risk factor for silent cerebral infarction (90).
Mean blood concentration of P-selectin within 7 days
of stroke onset was significantly higher compared to
controls (91). Ischemic stroke is a multicausal disorder
that results in enhanced thrombin generation, and the
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Table 3 The increase in platelet and soluble P-selectin in different vascular disorders.
References Type of Number Number P-selectin ratio
vascular of of
disorder patients controls Platelet Soluble
Blann AD et al. Blood Coagul Fibrinolysis 1996 (62) PVD 170 119 1.5
Furman MI et al. J Am Coll Cardiol 1998 (63) CAD 19 19 1.4
Gurbel PA et al. Am J Cardiol 2001 (60) Myocardial infarction 23 10 1.4 2.6
Ikeda H et al. Circulation 1995 (61) Unstable angina 23 15 2
Jilma B et al. Thromb Haemost 1996 (96) Type 1 diabetes 42 42 1.2
Kopp HP et al. Exp Clin Endocrinol Diabetes 1998 (97) Type 1 diabetes 18 18 1.9
Marquardt L et al. Stroke 2002 (88) Ischemic stroke 50 30 2
Minamino T et al. Circulation 1998 (90) Atrial fibrillation 25 25 1.6
Tschoepe D et al. Diabetes 1995 (95) Type 1 diabetes 21 50 5
Tschoepe D et al. Diabetologia 1997 (98) Type 1 diabetes 19 50 3.2
Yamazaki M et al. Thromb Res 2001 (89) Cerebral infarction 254 30 3
Zeiger F et al. Blood Coagul Fibrinolysis 2000 (99) PVD 50 50 1.4
Total: 714 458 Mean: 2.4 1.8
P-selectin values were expressed as patient/control ratio for both platelet and soluble P-selectin. PVD, peripheral vascular
disease.
observed cellular changes may be interrelated. In pre-
vious studies we observed elevation in the monocyte
tissue factor antigen and activity in early days after
ischemic stroke (92). This might be related to platelet
activation as platelets have been shown to be
involved in the generation of monocyte tissue factor
activity (93). These findings indicate the importance
of the detection of P-selectin expression in the iden-
tification of pre-thrombotic status.
Diabetes
The majority of the clinical studies investigating plate-
let or sPsel have been carried out on vascular disor-
ders and with hypercoagulability. All of these studies
reported an increase in P-selectin expression (Table
3). Patients with diabetes mellitus (DM) frequently
have hypercoagulable blood, as evidenced by
increased prothrombotic activity, depressed fibrinol-
ysis, reduced endothelial thromboresistance and
platelet hyperreactivity. These alterations lower the
coagulation threshold in the arterial circulation. The
increased functional properties of diabetic platelets
result from the primary release of larger platelets with
enhanced thromboxane formation capacity and
increased numbers of functional glycoprotein recep-
tors, GPIb and GPIIb/IIIa. The megakaryocyte-platelet
system is turned on in DM (94). The pathophysiolog-
ical development of atherothrombotic endpoints in
the diabetic environment starts with endothelial dys-
function and is mediated by accelerated atheroscle-
rosis. There is activation of exposed luminal adhesion
molecules, resulting in the adherence of white blood
cells and/or platelets. These changes favor repeated
acute occlusive thrombosis, which ultimately triggers
the gross infarct.
Tschoepe et al. reported that even patients with
newly diagnosed insulin-dependent diabetes mellitus
(IDDM) show clearly increased levels of circulating
activated platelets with exposed adhesion molecules.
The CD62q platelet levels were initially 5 times high-
er than that of controls (95). Others also found a high-
er median plasma level of circulating P-selectin in
patients with IDDM with increased P-selectin expres-
sion on platelets (96, 97). Moreover, this activation
was not related to the improvement of glycemic con-
trol with intensified insulin therapy. Most strikingly,
CD62P-positive platelets could also be found in met-
abolically healthy first-degree relatives of clinically
manifested type 1 diabetic patients. The mean num-
ber of CD62-positive platelets was increased 3.2-fold
in pre-diabetic patients. Thus, intravasal platelet acti-
vation is already present in potentially pre-diabetic
subjects (98). It is questionable whether hypercoagul-
ability in diabetes, including the hyperactivity of the
megakaryocyte-platelet system, can be normalized by
strict and effective near-normoglycemia alone (100).
Nevertheless it is interesting that even a minor ele-
vation of blood glucose in postprandial hyperglyce-
mia causing platelet hyperactivity can be monitored
by direct or indirect platelet activation assays (101,
102).
Malignancy
One area where the involvement of P-selectin has
been shown convincingly, both in experimental and
clinical studies, is oncology. The clinical prognosis
and metastatic progression of many epithelial carci-
nomas has been correlated with the production of
tumor mucins. Metastasis is thought to involve the
formation of tumor-platelet-leukocyte emboli and
their interaction with the endothelium of distant
organs. P-selectin that normally interacts with PSGL-
1 can facilitate the metastatic seeding of mucin-pro-
ducing carcinomas. This has clearly been verified in
P-selectin-deficient mice that displayed significantly
slower growth of subcutaneously implanted human
colon carcinoma cells and generated fewer lung
metastases from intravenously injected cells (103). In
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several clinical studies CD24, a heavily glycosylated
mucin, has been shown to be an independent prog-
nostic marker of survival in ovarian cancer (104) and
in non-small cell lung cancer (105). In addition, it has
also been shown that heparin treatment attenuates
tumor metastasis in mice by inhibiting P-selectin-
mediated interactions of platelets with carcinoma cell-
surface mucin ligands. Human P-selectin is evenmore
sensitive to heparin than mouse P-selectin, giving sig-
nificant inhibition at concentrations that are in the
clinically acceptable range. Heparin can block P-selec-
tin-based platelet interactions with tumor cell-surface
mucins and thereby attenuate metastasis. In vivo, P-
selectin-mediated tumor cell-platelet interaction is
impaired by mucin removal or by heparin treatment
(106).
Tumors have other means to enhance invasiveness
that are also P-selectin related. In melanomas a
reduced P-selectin expression was found in the tumor
endothelium. This suggests that a reduced expression
of P-selectin may contribute to a protective mecha-
nism in melanoma by preventing infiltration by leu-
kocytes (107). In addition to the role of cell-associated
P-selectin, the concentrations of sPsel, fibrinogen and
vWf are raised in patients with hematological and
breast cancer. vWf and sPsel are higher in the hema-
tological cancers than in breast cancer patients. The
sPsel as a platelet marker is unrelated to the type or
stage of breast cancer (58). These data suggest that
adhesion molecules may be useful targets for cancer
therapy and in cardiovascular disease.
Miscellaneous applications
Recently, some changes of platelets in patients with
depression were demonstrated. The number of GPIb
receptors on platelets was enhanced in depressed
patients. Surface expression of P-selectin was also
significantly increased in these patients as compared
to control subjects (108).
A possible emerging area of platelet and sPsel anal-
ysis could serve as therapy monitoring tests. The
effects of a single dose of aspirin on human platelets
can be measured by different flow cytometric meth-
ods including determination of CD62Pq platelet
percent. After using aspirin therapy, P-selectin
expression significantly decreased (109). Klinkhardt et
al. found clopidogrel or aspirin combined with clopi-
dogrel therapy more effective for reducing P-selectin
expression than aspirin treatment alone (64). The suc-
cess of thrombolytic therapy could also be followed
by soluble and platelet P-selectin measurements.
After thrombolytic therapy the sPsel level rapidly
returned toward baseline at 6 hours, although platelet
P-selectin showed only a moderate decrease in
patients with successful reperfusion (110). One further
application of the whole blood flow cytometric assay
of platelet function in PAD patients is the identifica-
tion of those patients who might benefit from addi-
tional antiplatelet therapy, like the ADP-receptor
antagonist clopidogrel in the case of very high ADP-
induced P-selectin levels on platelets (99).
PSGL-1 in health and disease
The expression of this dimeric glycoprotein on neu-
trophils, monocytes and T cells is important to medi-
ate these cells to roll on selectins (111). Later its
presence was described in several non-hematopoietic
tissues as well (112). The interaction of P-selectin with
PSGL-1 is a key element in many of the above listed
pathological states. It was not until the PSGL-1 knock-
out mouse was generated that the role of this
molecule became obvious in physiological and path-
ological states. The PSGL-1 knockout animals show
impaired tethering and rolling of myeloid cells on E-
selectin. In these knockout animals, the neutrophil
count is increased as cells are retained in the circu-
lation for a prolonged time (113). PSGL-1 may be
implicated in the adhesive events in leukemic cells, as
we have previously demonstrated the presence of a
differential expression pattern of PSGL-1 during mye-
loid hematopoietic development. In addition, the
quantification of surface PSGL-1 may help to differ-
entiate myeloblasts from monoblasts by immuno-
phenotyping (114). Though previous studies under-
line the harmful consequences of the P-selectin-PSGL-
1 interaction, it is interesting to note that a more
recent study has shown the beneficial values of this
interaction as it generates MPs that correct the bleed-
ing tendency in a mouse model of coagulopathy
(115). This means that the missing factor VIII can be
bypassed by providing another source of thrombin
generation. In addition, the soluble form of PSGL-1 is
now used as an effective P-selectin blocking agent at
both functional and molecular levels (116) that ame-
liorate coronary blood flow in various pathological
states.
In addition to being a platelet activation marker as
it was described two decades ago, P-selectin can now
be regarded as an important pathogenetic factor and
a disease marker. Aside from being a useful molecu-
lar marker, its interactions can be exploited for ther-
apeutic purposes as well.
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